<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Percutaneous coronary intervention of specific coronary lesions</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Percutaneous coronary intervention of specific coronary lesions</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Percutaneous coronary intervention of specific coronary lesions</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephan Windecker, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Percutaneous coronary intervention (PCI) refers to both nonstenting procedures and stent interventions. Stenting represented an advance over balloon angioplasty (percutaneous transluminal coronary angioplasty [PTCA]) alone because acute procedural success was higher and the rate of restenosis requiring target lesion revascularization was much lower. Approximately 20 to 30 percent of patients required clinically driven repeat target lesion revascularization within the first year after PTCA alone compared with 10 to 15 percent with bare-metal stents (BMS) [<a href="#rid1">1-3</a>].</p><p>Drug-eluting stents (DES) represented a further advance in PCI and are now used in almost all procedures. In addition, newer-generation DES have replaced first-generation DES, owing to reduced restenosis and stent thrombosis. (See  <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">"Intracoronary stents: Stent types", section on '2012 comparison of drug-eluting stents'</a> and  <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview", section on 'Role for bare metal stents'</a>.)</p><p>The use of PCI for specific coronary lesions will be reviewed here. The emphasis will be on the outcomes with DES. Issues related to the use of DES, the major clinical trials demonstrating the efficacy of DES compared to BMS, and the general principles of stent deployment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">SPECIFIC CORONARY LESIONS</span></p><p class="headingAnchor" id="H4"><span class="h2">Left main and left anterior descending disease</span><span class="headingEndMark"> — </span>Left main, left main equivalent, and proximal left anterior descending disease are associated with a relatively large amount of myocardium at risk. The possible indications for efficacy of drug-eluting stents (DES) with these lesions are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1544.html" rel="external">"Management of significant proximal left anterior descending coronary artery disease", section on 'PCI versus CABG'</a> and  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease", section on 'Feasibility and technical factors'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Multivessel revascularization</span><span class="headingEndMark"> — </span>The role of intracoronary stents for patients with multivessel coronary artery disease (CAD) is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus", section on 'PCI versus CABG'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Potential concerns</span><span class="headingEndMark"> — </span>There are potential concerns with multivessel and complex lesion treatment with DES that may limit its use compared to coronary artery bypass graft surgery (CABG) [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A higher risk of early and late stent thrombosis (5 of 17 [29 percent] in one series) in patients who prematurely discontinue antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher rate of repeat revascularization in patients undergoing PCI compared to CABG, especially in diabetic patients (12.6 versus 4.2 percent) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A greater likelihood that patients with PCI will have progressive coronary disease in areas not protected by stenting. In a review of 3747 PCIs from the National Heart, Lung, and Blood Institute Dynamic Registry, 216 (5.8 percent) required nontarget lesion PCI at one year; 87 percent of these nontarget lesions were ≤60 percent stenosis at initial PCI (mean 42 percent compared with 84 percent during the recurrent event) [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A greater likelihood of incomplete revascularization (IR) with PCI compared with CABG, particularly in patients with decreased left ventricular systolic function [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A higher risk of death and repeat revascularization in patients undergoing complete revascularization (CR) with PCI [<a href="#rid9">9-11</a>].</p><p></p><p class="headingAnchor" id="H149378448"><span class="h3">Complete versus incomplete revascularization</span><span class="headingEndMark"> — </span>Older studies of CABG suggest that CR is better than IR [<a href="#rid12">12</a>]. It is unclear whether this concept from revascularization with CABG extends to revascularization with PCI. There are no trials comparing CR to IR in patients with a similar burden of CAD, and the conclusions of observational studies differ:</p><p class="bulletIndent1"><span class="glyph">●</span>Outcomes after CR and IR were compared in a single-center registry report of 1914 patients undergoing PCI (n = 1400) with DES or CABG (n = 514) for multivessel CAD [<a href="#rid13">13</a>]. CR was achieved in 41 and 67 percent of those receiving PCI or CABG, respectively. Using a definition of CR (applied to the diagnostic angiogram) as any attempt to revascularize all disease segments ≥1.5 mm, no significant difference was found between those with CR and those with IR in the adjusted rates of five-year death (8.9 versus 8.9 percent; adjusted hazard ratio [HR] 1.04, 95% CI 0.76-1.43 respectively) or the composite of death, myocardial infarction (MI), or stroke (12.1 versus 11.9 percent; adjusted HR 1.04, 95% CI 0.79-1.36). The results were similar for analyses performed on only those patients who underwent PCI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a substudy of the SYNTAX trial, long-term rates of all-cause death were similar among patients randomly assigned to CABG who had CR or IR and patients assigned to PCI with a DES who had CR (23.8, 24.3, and 22.2 percent for CABG CR, CABG IR, and PCI CR, respectively) and higher in patients with PCI and IR (34 percent) [<a href="#rid14">14</a>]. Ten-year mortality rates were similar among patients who had CR with either CABG or PCI (adjusted HR 0.97; 95% CI 0.72-1.31). Regardless of random assignment to PCI or CABG, patients with less complete revascularization had a higher burden of CAD prior to revascularization (ie, SYNTAX score) and a higher prevalence of comorbidities, which may account for the higher mortality in patients with IR.</p><p></p><p>If a decision has been made to perform PCI rather than CABG in patients with refractory angina and multivessel disease, based on the available evidence, an attempt should be made to revascularize all lesions likely to impair coronary flow to moderate or large areas of viable myocardium. The results of noninvasive imaging techniques performed before PCI or the determination of fractional flow reserve during the procedure may be useful in this regard [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1579.html" rel="external">"Revascularization in patients with stable coronary artery disease: Coronary artery bypass graft surgery versus percutaneous coronary intervention"</a> and  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus", section on 'PCI versus CABG'</a> and  <a class="medical medical_review" href="/z/d/html/1514.html" rel="external">"Clinical use of coronary artery pressure flow measurements", section on 'Multivessel disease'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Ostial lesions</span><span class="headingEndMark"> — </span>Ostial lesions respond poorly to conventional balloon percutaneous transluminal coronary angioplasty (PTCA) because of inadequate dilation and elastic recoil. Stents may be an excellent treatment for elastic recoil, but efficacy is uncertain if debulking is also required.</p><p>Implantation must be precise to avoid positioning the stent too proximally, while assuring adequate coverage of ostial disease. Lack of optimal positioning can result in stent protrusion into the aorta, which may make repeat catheterization difficult or increase the risk for thromboembolic complications.</p><p>Data are limited on DES for ostial lesions but the benefit appears to be similar to that seen with other lesions [<a href="#rid16">16,17</a>]. The best data come from the SCANDSTENT trial in which 322 patients with symptomatic complex CAD were randomly assigned to PCI with a sirolimus-eluting or bare-metal stent (BMS) [<a href="#rid16">16</a>]. Among the 73 patients with ostial lesions, target lesion revascularization by seven months occurred only with BMS (0 versus 35 percent). In our experience, DES of the right coronary artery ostium has been associated with a higher frequency of clinically significant restenosis relative to other locations.</p><p>Lesions at the origin of the left anterior descending artery were evaluated in a study comparing <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> stents in 68 consecutive patients with such lesions to 77 patients treated with BMS during the preceding two years [<a href="#rid18">18</a>]. Positioning of the sirolimus stent into the distal left main trunk was required in one-third of patients for complete lesion coverage. The sirolimus stent was associated with significant reductions in angiographic restenosis at six months (5 versus 32 percent with BMS) and target vessel revascularization at one year (0 versus 17 percent).</p><p class="headingAnchor" id="H8"><span class="h2">Chronic total occlusion</span><span class="headingEndMark"> — </span>Chronic total occlusion (CTO) is defined as a 100 percent stenosis of a coronary artery with Thrombolysis In Myocardial Infarction (TIMI) 0 flow  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>) for more than three months (based on angiography or symptoms) [<a href="#rid19">19</a>]. Severe (but not total) occlusions with impaired flow are often referred to as "functional" CTOs, but such lesions are often technically less challenging to address percutaneously given the presence of an antegrade channel [<a href="#rid20">20</a>]. The full discussion of CTO is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/115590.html" rel="external">"Chronic total occlusion (CTO) in the coronary circulation"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Long lesions or diffuse disease</span><span class="headingEndMark"> — </span>Long stents or multiple stents may play an important role in the treatment of long lesions or diffuse disease. Restenosis rates are proportionally higher in longer lesions, but are lower than those associated with conventional PTCA. With BMS, longer stent segment length (&gt;35 mm) is associated with an increased risk of restenosis [<a href="#rid21">21</a>]. Although DES reduce the rate of restenosis, stent length &gt;35 mm is still a risk factor for restenosis [<a href="#rid22">22</a>].</p><p>Stent length should also be viewed in terms of lesion length. In the TAXUS IV trial of <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> stents, the operators were instructed to choose stent lengths to cover the lesion by 2 to 4 mm at each margin. Using longer stent-to-lesion lengths beyond that required to achieve this goal was of no benefit [<a href="#rid23">23</a>]. In the SIRIUS trial, excess stent length was associated with an increased risk for restenosis; the absolute increase in follow-up diameter stenosis per 10 mm excess stent length was 3.6 and 2.1 percent for bare-metal and DES, respectively [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Overlapping stents</span><span class="headingEndMark"> — </span>A potential concern with longer lesion treatment is that overlapping DES may result in adverse effects due to possible drug toxicity or polymer instability in the overlap segment. However, the use of multiple overlapping DES for very long lesions was relatively safe and associated with good intermediate-term outcomes in two small series [<a href="#rid25">25,26</a>].</p><p>In one of these reports, 66 patients with diffuse disease of the left anterior descending artery (average lesion length about 80 mm) were treated with multiple (mean 2.8) <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> stents [<a href="#rid25">25</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Angiographic and procedural success was achieved in 95 percent of patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eleven patients (17 percent) developed a non-ST-elevation MI in hospital, and one patient developed stent thrombosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At follow-up angiography at six months in 52 patients, 10 (19.6 percent) had restenosis; most of the lesions were focal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At an average follow-up of 13.6 months, there were no deaths, one patient had a non-ST-elevation MI, 10 (15 percent) required target vessel revascularization, and one patient required CABG.</p><p></p><p>Overlapping stents are associated with greater late lumen loss and more frequent angiographic restenosis than single stents. However, a subset analysis from three randomized trials and two prospective observational studies comparing <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> to BMS found that the magnitude of the restenosis benefit of sirolimus stents was similar in overlapping and single stents [<a href="#rid27">27</a>].</p><p>Concerns have been raised about possible persistent inflammation and delayed reendothelialization at overlapping compared to nonoverlapping sites. A pathologic study in a rabbit iliac artery model of overlapping <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> stents found evidence for increased inflammation and delayed healing for DES compared with BMS [<a href="#rid28">28</a>]. These changes were more pronounced at overlapping than nonoverlapping sites.</p><p class="headingAnchor" id="H11"><span class="h3">Very long lesions</span><span class="headingEndMark"> — </span>The efficacy of DES for very long lesions (median 79 mm, range 64 to 168 mm) was evaluated in a series of 122 patients with de novo lesions; multiple overlapping stents were used (mean 3.3 per lesion), an approach that has been called "full metal jacket" [<a href="#rid29">29</a>]. Periprocedural MI occurred in two patients (1.6 percent). At one year, the overall rate of major adverse cardiac events was 18 percent, including target vessel revascularization in only 7.5 percent, nonfatal MI in 8.2 percent, and death in 4.1 percent. There was only one case of subacute stent thrombosis and the outcomes were similar with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a> stents.</p><p class="headingAnchor" id="H12"><span class="h2">Bifurcation lesions</span><span class="headingEndMark"> — </span>Complex bifurcation lesions in the coronary arterial circulation generally have the following characteristics [<a href="#rid30">30,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>They involve the origin of a coronary artery side branch that is ≥2.5 mm in diameter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The side branch lesion length is at least 10 mm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The side branch diameter stenosis is ≥70 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Calcification, if present, would likely require atherectomy for side branch treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The side branch bifurcation angle is &lt;45 or &gt;70 degrees.</p><p></p><p>It has been estimated that bifurcation lesions are present in 15 to 20 percent of lesions treated at the time of PCI [<a href="#rid32">32</a>]. These lesions are more difficult to treat due in part to differences in anatomic patterns of stenosis, variations in the diameter of each of the branches, and the angle at which the side branch comes off the main branch. Some lesions are particularly challenging and have been called complex coronary bifurcation lesions.</p><p>The degree of ostial side branch stenosis is the primary determinant of the need for side branch protection. Treatment of bifurcation lesions with stenting has been associated with an increase in early complications, including compromise of the branch vessel or the target lesion, with the potential for MI, and enhanced potential for restenosis involving either the parent vessel or side branch. In addition, stenting may impair access to the side branch.</p><p>PCI with DES is performed in most patients [<a href="#rid33">33</a>]. In selected patients, a debulking procedure or calcification modification treatment such as rotational atherectomy is combined with DES. (See  <a class="medical medical_review" href="/z/d/html/1567.html" rel="external">"Specialized revascularization devices in the management of coronary heart disease"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Main versus main plus side branch stenting</span><span class="headingEndMark"> — </span>In most cases we suggest a strategy of main vessel only stenting with provisional stenting of the side branch ("provisional" approach) rather than a strategy of main plus side branch stenting, which has been referred to as "dedicated" or "complex" side branch stenting [<a href="#rid34">34-37</a>]. However, for patients with complex bifurcation lesions, a two-stent technique is a reasonable approach.</p><p>At least four randomized trials, each using somewhat different techniques, have compared these two approaches:</p><p class="bulletIndent1"><span class="glyph">●</span>In the TRYTON trial, 704 patients with bifurcation lesions were randomly assigned to a main vessel stent plus provisional stenting or a dedicated bifurcation stent [<a href="#rid38">38</a>]. The bifurcation stent, the Tryton Side Branch Stent, is a non-DES that requires implantation of a DES in the main branch to lock the device in place. At nine months, the rate of primary end point of target vessel failure (cardiac death, target vessel MI, and target vessel revascularization) was lower with provisional main vessel stenting (12.8 and 17.4 percent, respectively). The difference of 5.6 percent exceeded the pre-specified noninferiority margin for the bifurcation stent of 5.5 percent; the difference was primarily attributable to an increase in the rate of MI (10.1 versus 13.6 percent). In a subsequent single-arm registry and post-hoc analysis that was restricted to side branches &gt;2.25 mm in diameter, the Tryton device met a pre-specified performance goal and has received United States Federal Drug Administration approval for use in these larger side branches [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Nordic Bifurcation trial of 413 patients, there was no significant difference in the rate of major adverse cardiac events (MACE), defined as death, non-procedure-related MI, target vessel revascularization, or stent thrombosis, between the two-stent and provisional groups (3.4 versus 2.9 percent, respectively) at six months [<a href="#rid35">35</a>]. At five-year follow-up, freedom from MACE was not significantly different in the two groups (78.2 versus 84.2 percent, respectively) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the CACTUS trial of 350 patients, there was no significant difference in the rate of MACE (death, MI, and target vessel revascularization) between a two-stent technique with "crush stenting" and provisional groups (15.8 versus 15 percent respectively) at six months [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the BBC ONE trial of 500 patients, the primary end point (a composite of death, MI, and target-vessel failure) occurred significantly more often in the multistent group (15.2 versus 8.0 percent; HR 2.20, 95% CI 1.17-3.47), attributable principally to a significantly higher rate of MI (11.2 versus 3.6 percent) at nine months [<a href="#rid37">37</a>].</p><p></p><p>In these trials, patients assigned to complex procedures had statistically longer procedure and fluoroscopy times, higher contrast volumes, and higher rates of procedure-related increases in biomarkers of myocardial injury. The rate of side branch stenting in the provisional group of these studies varied from 4 to 30 percent.</p><p>Based upon the available evidence, including the fact that most side branches have a normal fractional flow reserve and presumed good outcome irrespective of angiographic severity [<a href="#rid41">41</a>], we recommend a strategy of limiting stent implantation to the main vessel using a DES for patients with bifurcation lesions. Side branch stent placement is appropriate for significant dissection, reduced flow (TIMI flow less than grade 3;  (<a class="graphic graphic_table graphicRef51941" href="/z/d/graphic/51941.html" rel="external">table 1</a>)), or clinical evidence of ischemia.</p><p>Patients who may benefit from a dedicated two-stent approach include those with complex bifurcation lesions [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease", section on 'Distal lesions'</a>.)</p><p>The DEFINITION II trial randomly assigned 653 patients with complex bifurcation lesions to a two-stent technique or provisional stenting. For the two-stent techniques, the DK crush (78 percent) or culotte stenting methods were strongly recommended [<a href="#rid43">43</a>] (see <a class="local">'Side branch stenting techniques'</a> below). In DEFINITION II, 29 percent of lesions were in the distal left main coronary artery. The primary endpoint (a composite of target lesion failure at one-year follow-up, including cardiac death, target vessel MI, and clinically driven target lesion revascularization) occurred in 11.4 and 6.1 percent of the two groups, respectively (HR 0.53, 95% CI 0.30-0.90). The findings in DEFINITION II are consistent with other studies [<a href="#rid42">42,44,45</a>].</p><p class="headingAnchor" id="H180724888"><span class="h3">Final kissing balloon dilation</span><span class="headingEndMark"> — </span>Although final kissing balloon inflation is always required with two-stent strategies, the issue of whether simultaneous balloon dilatation of both the main vessel and the side branch (final kissing balloon dilatation [FKBD]) is necessary after placement of a stent in only the main vessel was addressed in the Nordic-Baltic Bifurcation Study III [<a href="#rid46">46</a>]. In this trial, 477 patients with either stable or unstable disease and a bifurcation lesion were randomly assigned to either FKBD or no FKBD after stenting of the main vessel. Stenting of the side branch was allowed if, after FKBD, side branch TIMI flow grade was less than 3 (ie, less than normal flow which fills the distal bed completely).</p><p>At six months, there was no significant difference in the rate of the primary composite end point (cardiac death, non-procedure-related index lesion MI, target lesion revascularization, or definite stent thrombosis) between the FKBD and no FKBD groups (2.1 and 2.5 percent, respectively). As expected, based upon the experience comparing main versus main plus side branch stenting discussed in the preceding section, FKBD resulted in increased use of contrast media and longer procedure and fluoroscopy times. This is in contrast to dedicated two stent strategies, wherein FKBD is almost always advised.</p><p>We suggest FKBD in all two-stent approaches, but we suggest single-stent bifurcation treatment only in cases where there is reduced flow or other evidence of ischemic compromise involving a side branch that supplies at least a moderate myocardial territory.</p><p class="headingAnchor" id="H15"><span class="h3">Side branch stenting techniques</span><span class="headingEndMark"> — </span>When the side branch is stented, many techniques have been utilized and are discussed in detail elsewhere [<a href="#rid33">33</a>].</p><p>Summarized briefly:</p><p class="bulletIndent1"><span class="glyph">●</span>The simplest is provisional side branch stenting, in which a single stent is placed in the main vessel, and balloon dilation or stenting of the side branch is performed only if branch compromise ensues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pre-emptive stenting of both the main vessel and side branch, either by simultaneous inflation of the two stents side by side over a short distance proximal to the bifurcation (simultaneous kissing stents), "culotte" technique, in which a second stent is deployed through a strut of an initially placed stent in the parent vessel of side branch, overlapping the first stent for a short distance, or a variety of so-called "T" or "Y" techniques.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the crush technique, the proximal end of the stent in the side branch is crushed against the vessel wall as the second stent is deployed in the parent vessel in an attempt to optimize stent coverage of the entire plaque surface at the carina [<a href="#rid30">30,47-49</a>]. A final kissing balloon postdilation is essential and is performed by re-advancing a guidewire and angioplasty balloon through the sides of the parent vessel stent into the side branch and inflating simultaneously with a second balloon positioned within the parent stent. Most investigators have abandoned the basic technique due to lack of demonstrated benefit, possible increased safety concerns, and uncertainty of achieving final kissing balloon inflation in all cases. A modification of the technique has been developed using a two-step approach with one kissing inflation after initial stenting of the side branch and crush with a balloon in the main vessel and a second, or FKBD, after the main vessel stent is placed (the double kissing crush technique). As noted above, this technique has shown benefit over provisional stenting in complex left main CAD with true distal bifurcation stenosis involving both the left anterior descending and circumflex origins. (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease", section on 'Distal lesions'</a>.)</p><p></p><p>There is no consensus which two-stent technique is preferred in the treatment of non-left main bifurcation lesions, since most trials have not shown a planned two-stent approach to be superior to stenting of the main branch and rescue of the side branch with balloon angioplasty as needed. It is our practice to avoid side branch stents whenever possible. Regardless of technique, we recommend final kissing balloon inflation for optimal stent deployment whenever side branch stenting is required. Development of specially designed bifurcation stents may offer promise in the treatment of these complex lesions.</p><p class="headingAnchor" id="H16"><span class="h3">Left main disease</span><span class="headingEndMark"> — </span>Among patients with left main disease, a distal bifurcation lesion requiring a two-stent approach has been associated with higher rates of angiographic restenosis and target lesion revascularization after PCI with DES. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1555.html" rel="external">"Left main coronary artery disease", section on 'Distal lesions'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Small coronary arteries</span><span class="headingEndMark"> — </span>In general, and irrespective of the device used for PCI, the risk of restenosis after PCI is greater for small compared with large coronary arteries [<a href="#rid50">50-52</a>]. For most patients who need PCI of one or more lesions in a small coronary artery (≥2 to &lt;3 mm), we use either a DES or a drug-coated balloon (DCB). DCBs are not available in the United States.</p><p>Randomized trials before the availability of DES suggested that BMS in small coronary arteries did not improve long-term outcomes compared to conventional balloon angioplasty, provided that dilatation produced a satisfactory initial result [<a href="#rid53">53</a>]. Stents were beneficial if the results of balloon angioplasty were suboptimal with a persistent significant residual stenosis. The efficacy of the first-generation <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> stent compared to BMS in small coronary arteries was evaluated in three randomized trials, E-SIRIUS, SES-SMART, and TAXUS V [<a href="#rid54">54-56</a>]. Relatively small studies of early-generation DES found that DES, compared with BMS, was associated with significant reductions in restenosis within the lesion ≥50 percent diameter (6 versus 42 percent) and the rate of target vessel revascularization (4 versus 21 percent).</p><p>Small studies have compared DCB with DES in small vessels [<a href="#rid57">57-59</a>]. In the BASKET-Small 2 all-comer population trial, 758 patients with de novo lesions less than 3 mm in diameter were randomly assigned to receive angioplasty with DCB or implantation of a second-generation DES [<a href="#rid59">59</a>]. After 12 months, there was no difference in the rate of the combined outcome of cardiac death, nonfatal MI, and target-vessel revascularization (7.5 versus 7.3 percent; HR 0.97, 95% CI 0.58-1.64; p-value for noninferiority 0.0217). Efficacy and safety of DCB were maintained for up to three years [<a href="#rid60">60</a>].</p><p>At least two newer generation DES designed for very small vessels have been approved [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H18"><span class="h2">Large coronary arteries</span><span class="headingEndMark"> — </span>When evaluating outcomes in patients with large coronary arteries (≥3.0 mm in diameter), two points should be kept in mind:</p><p class="bulletIndent1"><span class="glyph">●</span>The rate of target lesion revascularization (TLR) is lower in large compared to small coronary arteries after stenting with either BMS or DES [<a href="#rid63">63-66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the broad population of patients who undergo PCI with stenting, DES reduce the rate of TLR compared with BMS, while the risks of death and MI are similar. (See  <a class="medical medical_review" href="/z/d/html/1575.html" rel="external">"Intracoronary stents: Stent types", section on 'Bare metal stents'</a>.)</p><p></p><p>In the subset of patients with large coronary arteries (≥3.0 mm in diameter), we believe evidence allows for the following conclusions regarding efficacy and safety comparing DES to BMS:</p><p class="bulletIndent1"><span class="glyph">●</span>The rate of TLR is equivalent or lower with DES compared to BMS [<a href="#rid56">56,66,67</a>], but the lower TLR rate in larger vessels makes the absolute benefits lower.</p><p></p><p class="bulletIndent1">As the benefit from a reduction in TLR with DES compared with BMS declines in large vessels, any potential increase in risk associated with the use of DES becomes increasingly important. Retrospective analyses have raised the possibility of a possible increase in risk (cardiac death or MI) with DES in these vessels [<a href="#rid67">67-69</a>]. The BASKET-PROVE trial attempted to directly address this issue by randomly assigning 2314 patients needing stents 3.0 mm or greater in diameter to receive sirolimus-eluting stents, everolimus-eluting stents, or BMS [<a href="#rid70">70</a>]. While the rate of the primary end point (composite of death from cardiac causes or nonfatal MI at two years) was <strong>lower</strong> with the two DES (2.6 versus 3.2 versus 4.8 percent for sirolimus-eluting stents, everolimus-eluting stents, and BMS, respectively), these differences did not achieve statistical significance. This was due in part to unexpectedly low event rates, causing the trial to be underpowered to address the issue. Based on these data and evidence for improved safety and effectiveness for newer-generation DES in other lesions, we prefer DES over BMS in large vessels as long as DES can accommodate the vessel diameter.</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Acute vessel closure or dissection</span><span class="headingEndMark"> — </span>Stenting is the treatment of choice for either acute or threatened closure complicating PTCA and for the treatment of dissection; the goal is to restore TIMI 3 flow. In addition, acute or threatened closure may complicate predilation, stent deployment, or postdilation during a planned stent procedure and require the placements of additional stents to achieve optimal results. Failure to adequately restore flow or leaving untreated dissections significantly increases the risk for subacute thrombosis.</p><p>For treatment of acute closure or extensive dissections, the operator must consider other factors that may jeopardize the final result, including the relative size of the vessel, the inflow of blood into the treated segment, and the distal runoff. When either the flow into the artery or distal runoff is compromised, there is an increased risk for acute and subacute stent thrombosis, which may negate the beneficial effects of additional stenting. Smaller caliber vessels treated with smaller diameter stents also have an increased likelihood for subacute thrombosis compared to larger vessels treated with larger diameter stents.</p><p>Emergency surgery may be required in some situations, such as dissection of the left main artery or significant bifurcations, refractory thrombosis, loss of guide wire access, or inability to perform stenting.</p><p class="headingAnchor" id="H20"><span class="h1">SPECIFIC CLINICAL SETTINGS</span><span class="headingEndMark"> — </span>In addition to their use for specific coronary artery lesions, intracoronary stents, particularly drug-eluting stents, have been used in specific clinical settings in addition with stable or unstable angina. Their efficacy in these settings is discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>Saphenous vein graft stenosis. (See  <a class="medical medical_review" href="/z/d/html/1565.html" rel="external">"Coronary artery bypass graft surgery: Prevention and management of vein graft stenosis", section on 'Outcomes with PCI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In-stent restenosis. (See  <a class="medical medical_review" href="/z/d/html/1587.html" rel="external">"Intracoronary stent restenosis", section on 'Choice of device'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary percutaneous coronary intervention for ST-elevation MI. (See  <a class="medical medical_review" href="/z/d/html/15358.html" rel="external">"Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Periprocedural management", section on 'Selection of stent type'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non-ST-elevation acute coronary syndrome. (See  <a class="medical medical_review" href="/z/d/html/46.html" rel="external">"Non-ST-elevation acute coronary syndromes: Selecting an approach to revascularization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diabetic patients. (See  <a class="medical medical_review" href="/z/d/html/1581.html" rel="external">"Coronary artery revascularization in stable patients with diabetes mellitus", section on 'Stent type'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Women. (See  <a class="medical medical_review" href="/z/d/html/1520.html" rel="external">"Management of coronary heart disease in women"</a>.)</p><p></p><p class="headingAnchor" id="H226885088"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119297.html" rel="external">"Society guideline links: Percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon. Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/3434.html" rel="external">"Patient education: Stenting for the heart (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H22"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction </strong>– Drug-eluting stents (DES) are now used almost exclusively in percutaneous coronary intervention (PCI) procedures, as they significantly reduce the risk of target lesion revascularization compared with bare-metal stents. (See  <a class="medical medical_review" href="/z/d/html/1569.html" rel="external">"Percutaneous coronary intervention with intracoronary stents: Overview", section on 'Role for bare metal stents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of percutaneous coronary intervention </strong>–<strong> </strong>This benefit of DES has been demonstrated in a broad array of lesion types including multivessel, ostial, chronic total occlusion, and long lesions, as well as in small coronary arteries. However, coronary artery bypass graft surgery should be considered in some patients such as those with a high risk of coronary artery stent thrombosis and lesions that cannot be adequately revascularized with PCI, as well as some patients with diabetes or left main coronary artery disease. (See <a class="local">'Specific coronary lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific clinical settings </strong>–<strong> </strong>In addition to specific lesion types, DES are of benefit in specific clinical situations such as in patients with diabetes, acute coronary syndromes, vein graft lesions, and in-stent restenosis. (See <a class="local">'Specific clinical settings'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.</a></li><li><a class="nounderline abstract_t">Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.</a></li><li><a class="nounderline abstract_t">Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40:2082.</a></li><li><a class="nounderline abstract_t">Klein LW. Are drug-eluting stents the preferred treatment for multivessel coronary artery disease? J Am Coll Cardiol 2006; 47:22.</a></li><li><a class="nounderline abstract_t">Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.</a></li><li><a class="nounderline abstract_t">Macaya C, García-García HM, Colombo A, et al. One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS-II and ARTS-I. EuroIntervention 2006; 2:69.</a></li><li><a class="nounderline abstract_t">Glaser R, Selzer F, Faxon DP, et al. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 2005; 111:143.</a></li><li><a class="nounderline abstract_t">Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease? Am Heart J 2010; 159:141.</a></li><li><a class="nounderline abstract_t">Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113:2406.</a></li><li><a class="nounderline abstract_t">Hannan EL, Wu C, Walford G, et al. Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes. JACC Cardiovasc Interv 2009; 2:17.</a></li><li><a class="nounderline abstract_t">van den Brand MJ, Rensing BJ, Morel MA, et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 2002; 39:559.</a></li><li><a class="nounderline abstract_t">Ong AT, Serruys PW. Complete revascularization: coronary artery bypass graft surgery versus percutaneous coronary intervention. Circulation 2006; 114:249.</a></li><li><a class="nounderline abstract_t">Kim YH, Park DW, Lee JY, et al. Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease. Circulation 2011; 123:2373.</a></li><li><a class="nounderline abstract_t">Takahashi K, Serruys PW, Gao C, et al. Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation 2021; 144:96.</a></li><li><a class="nounderline abstract_t">Dauerman HL. Reasonable incomplete revascularization. Circulation 2011; 123:2337.</a></li><li><a class="nounderline abstract_t">Kelbaek H, Thuesen L, Helqvist S, et al. The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. J Am Coll Cardiol 2006; 47:449.</a></li><li><a class="nounderline abstract_t">Iakovou I, Ge L, Michev I, et al. Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions. J Am Coll Cardiol 2004; 44:967.</a></li><li><a class="nounderline abstract_t">Seung KB, Kim YH, Park DW, et al. Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance. J Am Coll Cardiol 2005; 46:787.</a></li><li><a class="nounderline abstract_t">Stone GW, Kandzari DE, Mehran R, et al. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. Circulation 2005; 112:2364.</a></li><li><a class="nounderline abstract_t">Ivanhoe RJ, Weintraub WS, Douglas JS Jr, et al. Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up. Circulation 1992; 85:106.</a></li><li><a class="nounderline abstract_t">Kobayashi Y, De Gregorio J, Kobayashi N, et al. Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol 1999; 34:651.</a></li><li><a class="nounderline abstract_t">Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366.</a></li><li><a class="nounderline abstract_t">Wong SC, Hong MK, Ellis SG, et al. Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study). Am J Cardiol 2005; 95:1043.</a></li><li><a class="nounderline abstract_t">Mauri L, O'Malley AJ, Popma JJ, et al. Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents. Am J Cardiol 2005; 95:1140.</a></li><li><a class="nounderline abstract_t">Tsagalou E, Chieffo A, Iakovou I, et al. Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery. J Am Coll Cardiol 2005; 45:1570.</a></li><li><a class="nounderline abstract_t">Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus-eluting stent implantation for de novo coronary lesions. Am J Cardiol 2004; 93:826.</a></li><li><a class="nounderline abstract_t">Kereiakes DJ, Wang H, Popma JJ, et al. Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials. J Am Coll Cardiol 2006; 48:21.</a></li><li><a class="nounderline abstract_t">Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005; 112:270.</a></li><li><a class="nounderline abstract_t">Aoki J, Ong AT, Rodriguez Granillo GA, et al. "Full metal jacket" (stented length &gt; or =64 mm) using drug-eluting stents for de novo coronary artery lesions. Am Heart J 2005; 150:994.</a></li><li><a class="nounderline abstract_t">Williams DO, Abbott JD. Bifurcation intervention: is it crush time yet? J Am Coll Cardiol 2005; 46:621.</a></li><li><a class="nounderline abstract_t">Garot P, Lefèvre T, Savage M, et al. Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. J Am Coll Cardiol 2005; 46:606.</a></li><li><a class="nounderline abstract_t">Latib A, Colombo A. Bifurcation disease: what do we know, what should we do? JACC Cardiovasc Interv 2008; 1:218.</a></li><li><a class="nounderline abstract_t">Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46:1446.</a></li><li><a class="nounderline abstract_t">Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation 2004; 109:1244.</a></li><li><a class="nounderline abstract_t">Steigen TK, Maeng M, Wiseth R, et al. Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 2006; 114:1955.</a></li><li><a class="nounderline abstract_t">Colombo A, Bramucci E, Saccà S, et al. Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study. Circulation 2009; 119:71.</a></li><li><a class="nounderline abstract_t">Hildick-Smith D, de Belder AJ, Cooter N, et al. Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies. Circulation 2010; 121:1235.</a></li><li><a class="nounderline abstract_t">Généreux P, Kumsars I, Lesiak M, et al. A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions. J Am Coll Cardiol 2015; 65:533.</a></li><li><a class="nounderline abstract_t">Généreux P, Kumsars I, Schneider JE, et al. Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study. JACC Cardiovasc Interv 2016; 9:1338.</a></li><li><a class="nounderline abstract_t">Maeng M, Holm NR, Erglis A, et al. Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results. J Am Coll Cardiol 2013; 62:30.</a></li><li><a class="nounderline abstract_t">Koo BK, Kang HJ, Youn TJ, et al. Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol 2005; 46:633.</a></li><li><a class="nounderline abstract_t">Chen SL, Zhang JJ, Han Y, et al. Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial. J Am Coll Cardiol 2017; 70:2605.</a></li><li><a class="nounderline abstract_t">Zhang JJ, Ye F, Xu K, et al. Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial. Eur Heart J 2020; 41:2523.</a></li><li><a class="nounderline abstract_t">Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial. J Am Coll Cardiol 2011; 57:914.</a></li><li><a class="nounderline abstract_t">Chen SL, Xu B, Han YL, et al. Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study. J Am Coll Cardiol 2013; 61:1482.</a></li><li><a class="nounderline abstract_t">Niemelä M, Kervinen K, Erglis A, et al. Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 2011; 123:79.</a></li><li><a class="nounderline abstract_t">Ge L, Airoldi F, Iakovou I, et al. Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol 2005; 46:613.</a></li><li><a class="nounderline abstract_t">Costa RA, Mintz GS, Carlier SG, et al. Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis. J Am Coll Cardiol 2005; 46:599.</a></li><li><a class="nounderline abstract_t">Moussa I, Costa RA, Leon MB, et al. A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique". Am J Cardiol 2006; 97:1317.</a></li><li><a class="nounderline abstract_t">Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006; 48:1304.</a></li><li><a class="nounderline abstract_t">Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999; 34:40.</a></li><li><a class="nounderline abstract_t">Siontis GC, Piccolo R, Praz F, et al. Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis. JACC Cardiovasc Interv 2016; 9:1324.</a></li><li><a class="nounderline abstract_t">Agostoni P, Biondi-Zoccai GG, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J 2005; 26:881.</a></li><li><a class="nounderline abstract_t">Schofer J, Schlüter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362:1093.</a></li><li><a class="nounderline abstract_t">Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292:2727.</a></li><li><a class="nounderline abstract_t">Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005; 294:1215.</a></li><li><a class="nounderline abstract_t">Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010; 96:1291.</a></li><li><a class="nounderline abstract_t">Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012; 60:2473.</a></li><li><a class="nounderline abstract_t">Jeger RV, Farah A, Ohlow MA, et al. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet 2018; 392:849.</a></li><li><a class="nounderline abstract_t">Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020; 396:1504.</a></li><li><a class="nounderline abstract_t">Price MJ, Saito S, Shlofmitz RA, et al. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. JACC Cardiovasc Interv 2017; 10:1381.</a></li><li><a class="nounderline abstract_t">Cannon LA, Simon DI, Kereiakes D, et al. The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial. Catheter Cardiovasc Interv 2012; 80:546.</a></li><li><a class="nounderline abstract_t">Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315.</a></li><li><a class="nounderline abstract_t">Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221.</a></li><li><a class="nounderline abstract_t">Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000; 21:1739.</a></li><li><a class="nounderline abstract_t">Steinberg DH, Mishra S, Javaid A, et al. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (&gt; or =3.5 mm) coronary arteries. Am J Cardiol 2007; 99:599.</a></li><li><a class="nounderline abstract_t">Brunner-La Rocca HP, Kaiser C, Pfisterer M, BASKET Investigators. Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007; 28:719.</a></li><li><a class="nounderline abstract_t">Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, et al. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30:16.</a></li><li><a class="nounderline abstract_t">Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007; 357:1393.</a></li><li><a class="nounderline abstract_t">Kaiser C, Galatius S, Erne P, et al. Drug-eluting versus bare-metal stents in large coronary arteries. N Engl J Med 2010; 363:2310.</a></li></ol></div><div id="topicVersionRevision">Topic 1571 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041414" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041413" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12505217" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16386659" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Are drug-eluting stents the preferred treatment for multivessel coronary artery disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19755239" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : One-year results of coronary revascularization in diabetic patients with multivessel coronary artery disease.Sirolimus stent vs. coronary artery bypass surgery and bare metal stent: insights from ARTS-II and ARTS-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623544" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20102880" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel coronary artery disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16702469" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463393" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11849851" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The effect of completeness of revascularization on event-free survival at one year in the ARTS trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16847164" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Complete revascularization: coronary artery bypass graft surgery versus percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576650" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of angiographic complete revascularization after drug-eluting stent implantation or coronary artery bypass graft surgery for multivessel coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34011163" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576647" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reasonable incomplete revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412876" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15337205" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical and angiographic outcome after sirolimus-eluting stent implantation in aorto-ostial lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16139126" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effectiveness of sirolimus-eluting stent implantation for the treatment of ostial left anterior descending artery stenosis with intravascular ultrasound guidance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16216980" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728439" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Percutaneous transluminal coronary angioplasty of chronic total occlusions. Primary success, restenosis, and long-term clinical follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10483943" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Stented segment length as an independent predictor of restenosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14993127" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15842968" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877983" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of thrombosis and restenosis risk from stent length of sirolimus-eluting stents versus bare metal stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15893168" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multiple overlapping drug-eluting stents to treat diffuse disease of the left anterior descending coronary artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15050483" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Very long sirolimus-eluting stent implantation for de novo coronary lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814644" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15998681" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16290984" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : "Full metal jacket" (stented length&gt;or =64 mm) using drug-eluting stents for de novo coronary artery lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098425" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Bifurcation intervention: is it crush time yet?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098423" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nine-month outcome of patients treated by percutaneous coronary interventions for bifurcation lesions in the recent era: a report from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19463303" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Bifurcation disease: what do we know, what should we do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16226167" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Contemporary stent treatment of coronary bifurcations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981005" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060387" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19103990" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194880" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Randomized trial of simple versus complex drug-eluting stenting for bifurcation lesions: the British Bifurcation Coronary Study: old, new, and evolving strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25677311" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized trial of a dedicated bifurcation stent versus provisional stenting in the treatment of coronary bifurcation lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27388820" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Dedicated Bifurcation Stent for the Treatment of Bifurcation Lesions Involving Large Side Branches: Outcomes From the Tryton Confirmatory Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644088" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term results after simple versus complex stenting of coronary artery bifurcation lesions: Nordic Bifurcation Study 5-year follow-up results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098427" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Physiologic assessment of jailed side branch lesions using fractional flow reserve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096915" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Double Kissing Crush Versus Provisional Stenting for Left Main Distal Bifurcation Lesions: DKCRUSH-V Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32588060" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21329837" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23490040" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparison of double kissing crush versus Culotte stenting for unprotected distal left main bifurcation lesions: results from a multicenter, randomized, prospective DKCRUSH-III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21173348" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098424" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098422" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bifurcation coronary lesions treated with the "crush" technique: an intravascular ultrasound analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16635603" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010786" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10399990" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27318845" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681573" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14550694" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585732" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16160130" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20659948" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23158530" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30170854" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33091360" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28728650" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22121027" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The XIENCE nano everolimus eluting coronary stent system for the treatment of small coronary arteries: the SPIRIT Small Vessel trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14523139" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724301" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11052838" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Coronary in-stent restenosis - predictors, treatment and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17317356" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (&gt;or =3.5 mm) coronary arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17298975" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Targeted stent use in clinical practice based on evidence from the Basel Stent Cost Effectiveness Trial (BASKET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19033260" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914040" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effectiveness and safety of drug-eluting stents in Ontario.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21080780" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Drug-eluting versus bare-metal stents in large coronary arteries.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
